-
1
-
-
0025573030
-
Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism
-
Gerstman B., Piper J., Freiman J., et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 19 (1990) 931-936
-
(1990)
Int J Epidemiol
, vol.19
, pp. 931-936
-
-
Gerstman, B.1
Piper, J.2
Freiman, J.3
-
2
-
-
0026078062
-
Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
-
Gerstman B., Piper J., Tomita D., Ferguson W., Stadel B., and Lundin F. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133 (1991) 32-37
-
(1991)
Am J Epidemiol
, vol.133
, pp. 32-37
-
-
Gerstman, B.1
Piper, J.2
Tomita, D.3
Ferguson, W.4
Stadel, B.5
Lundin, F.6
-
3
-
-
0023204821
-
Venous thromboembolism in relation to oral contraceptive use
-
Helmrich S., Rosenberg L., Kaufman D., Strom B., and Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 69 (1987) 91-95
-
(1987)
Obstet Gynecol
, vol.69
, pp. 91-95
-
-
Helmrich, S.1
Rosenberg, L.2
Kaufman, D.3
Strom, B.4
Shapiro, S.5
-
4
-
-
13344260005
-
Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
-
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception
-
World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346 (1995) 1582-1588
-
(1995)
Lancet
, vol.346
, pp. 1582-1588
-
-
-
5
-
-
0029609256
-
Enhancement by factor V. Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
-
Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., Buller H.R., and Vandenbroucke J.P. Enhancement by factor V. Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346 (1995) 1593-1596
-
(1995)
Lancet
, vol.346
, pp. 1593-1596
-
-
Bloemenkamp, K.W.1
Rosendaal, F.R.2
Helmerhorst, F.M.3
Buller, H.R.4
Vandenbroucke, J.P.5
-
6
-
-
0029586002
-
Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
-
Jick H., Jick S.S., Gurewich V., Myers M.W., and Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
-
(1995)
Lancet
, vol.346
, pp. 1589-1593
-
-
Jick, H.1
Jick, S.S.2
Gurewich, V.3
Myers, M.W.4
Vasilakis, C.5
-
7
-
-
0029671042
-
Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women
-
Spitzer W.O., Lewis M.A., Heinemann L.A., Thorogood M., and MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ 312 (1996) 83-88
-
(1996)
BMJ
, vol.312
, pp. 83-88
-
-
Spitzer, W.O.1
Lewis, M.A.2
Heinemann, L.A.3
Thorogood, M.4
MacRae, K.D.5
-
8
-
-
0034070719
-
A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives
-
Farmer R., Lawrenson R., Todd J., et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 49 (2000) 580-590
-
(2000)
Br J Clin Pharmacol
, vol.49
, pp. 580-590
-
-
Farmer, R.1
Lawrenson, R.2
Todd, J.3
-
9
-
-
0033028472
-
Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database
-
Todd J., Lawrenson R., Farmer R., Williams T., and Leydon G. Venous thromboembolic disease and combined oral contraceptives: a re-analysis of the MediPlus database. Hum Reprod 14 (1999) 1500-1505
-
(1999)
Hum Reprod
, vol.14
, pp. 1500-1505
-
-
Todd, J.1
Lawrenson, R.2
Farmer, R.3
Williams, T.4
Leydon, G.5
-
10
-
-
0033709889
-
Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism
-
discussion 37S-38S
-
Winkler U. Hemostatic effects of third- and second-generation oral contraceptives: absence of a causal mechanism for a difference in risk of venous thromboembolism. Contraception 62 (2000) 11S-20S discussion 37S-38S
-
(2000)
Contraception
, vol.62
-
-
Winkler, U.1
-
11
-
-
69949088549
-
Hormonal contraception and risk of venous thromboembolism: national follow-up study
-
Lidegaard O., Lokkegaard E., Svendsen A.L., and Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 339 (2009) b2890
-
(2009)
BMJ
, vol.339
-
-
Lidegaard, O.1
Lokkegaard, E.2
Svendsen, A.L.3
Agger, C.4
-
12
-
-
69949103268
-
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
-
van Hylckama Vlieg A., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J., and Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 339 (2009) b2921
-
(2009)
BMJ
, vol.339
-
-
van Hylckama Vlieg, A.1
Helmerhorst, F.M.2
Vandenbroucke, J.P.3
Doggen, C.J.4
Rosendaal, F.R.5
-
13
-
-
0036237681
-
Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study
-
Schramm G., and Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2 mg/ethinylestradiol 0.03 mg (Belara®). Results of a post-marketing surveillance study. Clin Drug Invest 22 (2002) 221-231
-
(2002)
Clin Drug Invest
, vol.22
, pp. 221-231
-
-
Schramm, G.1
Steffens, D.2
-
14
-
-
0037383049
-
A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties
-
Schramm G., and Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara: efficacy, tolerability and anti-androgenic properties. Contraception 67 (2003) 305-312
-
(2003)
Contraception
, vol.67
, pp. 305-312
-
-
Schramm, G.1
Steffens, D.2
-
15
-
-
0031958753
-
Efficacy and safety of the new antiandrogenic oral contraceptive Belara
-
Zahradnik H.P., Goldberg J., and Andreas J.O. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception 57 (1998) 103-109
-
(1998)
Contraception
, vol.57
, pp. 103-109
-
-
Zahradnik, H.P.1
Goldberg, J.2
Andreas, J.O.3
-
16
-
-
41549091883
-
Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based Phase III study
-
Zahradnik H.P., and Hanjalic-Beck A. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) - an open-label, prospective, noncontrolled, office-based Phase III study. Contraception 77 (2008) 337-343
-
(2008)
Contraception
, vol.77
, pp. 337-343
-
-
Zahradnik, H.P.1
Hanjalic-Beck, A.2
-
17
-
-
1842689291
-
Ethinylestradiol/chlormadinone acetate
-
[discussion 61-2]
-
Curran M.P., and Wagstaff A.J. Ethinylestradiol/chlormadinone acetate. Drugs 64 (2004) 751-760 [discussion 61-2]
-
(2004)
Drugs
, vol.64
, pp. 751-760
-
-
Curran, M.P.1
Wagstaff, A.J.2
-
18
-
-
0034838348
-
Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon)
-
Worret I., Arp W., Zahradnik H.P., Andreas J.O., and Binder N. Acne resolution rates: results of a single-blind, randomized, controlled, parallel phase III trial with EE/CMA (Belara) and EE/LNG (Microgynon). Dermatology 203 (2001) 38-44
-
(2001)
Dermatology
, vol.203
, pp. 38-44
-
-
Worret, I.1
Arp, W.2
Zahradnik, H.P.3
Andreas, J.O.4
Binder, N.5
-
19
-
-
29044442795
-
Belara - a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea
-
Zahradnik H.P. Belara - a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur J Contracept Reprod Health Care 10 Suppl 1 (2005) 12-18
-
(2005)
Eur J Contracept Reprod Health Care
, vol.10
, Issue.SUPPL. 1
, pp. 12-18
-
-
Zahradnik, H.P.1
-
20
-
-
0032253933
-
Recommendations for oral contraception. 20th Professional Meeting of the Zurich Discussion Group, April 1998
-
Birkhauser M., Braendle W., Breckwoldt M., Keller P.J., Kuhl H., and Runnebaum B. Recommendations for oral contraception. 20th Professional Meeting of the Zurich Discussion Group, April 1998. Gynakol Geburtshilfliche Rundsch 38 (1998) 164-165
-
(1998)
Gynakol Geburtshilfliche Rundsch
, vol.38
, pp. 164-165
-
-
Birkhauser, M.1
Braendle, W.2
Breckwoldt, M.3
Keller, P.J.4
Kuhl, H.5
Runnebaum, B.6
-
21
-
-
85052549916
-
Combined oral contraceptives. A statement by the Committee on Safety of Drugs
-
Combined oral contraceptives. A statement by the Committee on Safety of Drugs. Br Med J 2 (1970) 231-232
-
(1970)
Br Med J
, vol.2
, pp. 231-232
-
-
-
22
-
-
84975926180
-
R.C.O.G. statement on oral contraceptives
-
Jeffcoate T.N. R.C.O.G. statement on oral contraceptives. Br Med J 2 (1970) 293
-
(1970)
Br Med J
, vol.2
, pp. 293
-
-
Jeffcoate, T.N.1
-
23
-
-
18544395394
-
Recommendations for oral contraception. 24th meeting of the "Zurich Discussion Circle"
-
Birkhauser M., Braendle W., Breckwoldt M., Keller P.J., Kuhl H., and Runnebaum B. Recommendations for oral contraception. 24th meeting of the "Zurich Discussion Circle". Gynakol Geburtshilfliche Rundsch 40 (2000) 172-175
-
(2000)
Gynakol Geburtshilfliche Rundsch
, vol.40
, pp. 172-175
-
-
Birkhauser, M.1
Braendle, W.2
Breckwoldt, M.3
Keller, P.J.4
Kuhl, H.5
Runnebaum, B.6
-
24
-
-
0030222154
-
Shorter pill-free interval in combined oral contraceptives decreases follicular development
-
Spona J., Elstein M., Feichtinger W., et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception 54 (1996) 71-77
-
(1996)
Contraception
, vol.54
, pp. 71-77
-
-
Spona, J.1
Elstein, M.2
Feichtinger, W.3
-
25
-
-
0033168809
-
Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity
-
Sullivan H., Furniss H., Spona J., and Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 72 (1999) 115-120
-
(1999)
Fertil Steril
, vol.72
, pp. 115-120
-
-
Sullivan, H.1
Furniss, H.2
Spona, J.3
Elstein, M.4
-
28
-
-
0012431804
-
Report of the expert committee on the diagnosis and classification of diabetes mellitus
-
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1 (2003) S5-S20
-
(2003)
Diabetes Care
, vol.26
, Issue.SUPPL. 1
-
-
-
29
-
-
0031851293
-
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation
-
Alberti K.G., and Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15 (1998) 539-553
-
(1998)
Diabet Med
, vol.15
, pp. 539-553
-
-
Alberti, K.G.1
Zimmet, P.Z.2
-
30
-
-
19444379341
-
Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism
-
Klipping C., and Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 71 (2005) 409-416
-
(2005)
Contraception
, vol.71
, pp. 409-416
-
-
Klipping, C.1
Marr, J.2
-
31
-
-
0037369726
-
The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study
-
The Oral Contraceptive and Hemostasis Study Group
-
The Oral Contraceptive and Hemostasis Study Group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: conclusions from a large randomized multicenter study. Contraception 67 (2003) 173-185
-
(2003)
Contraception
, vol.67
, pp. 173-185
-
-
-
32
-
-
33644862743
-
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol
-
Kluft C., Endrikat J., Mulder S.M., Gerlinger C., and Heithecker R. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 73 (2006) 336-343
-
(2006)
Contraception
, vol.73
, pp. 336-343
-
-
Kluft, C.1
Endrikat, J.2
Mulder, S.M.3
Gerlinger, C.4
Heithecker, R.5
-
33
-
-
33644817742
-
Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters
-
Aldrighi J.M., De Campos L.S., Eluf Gebara O.C., Petta C.A., and Bahamondes L. Effect of a combined oral contraceptive containing 20 microg ethinyl estradiol and 75 microg gestodene on hemostatic parameters. Gynecol Endocrinol 22 (2006) 1-4
-
(2006)
Gynecol Endocrinol
, vol.22
, pp. 1-4
-
-
Aldrighi, J.M.1
De Campos, L.S.2
Eluf Gebara, O.C.3
Petta, C.A.4
Bahamondes, L.5
-
34
-
-
22044452540
-
A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel
-
Jespersen J., Endrikat J., Dusterberg B., et al. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel. Contraception 72 (2005) 98-104
-
(2005)
Contraception
, vol.72
, pp. 98-104
-
-
Jespersen, J.1
Endrikat, J.2
Dusterberg, B.3
-
35
-
-
34047263992
-
The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation
-
Dinger J.C., Heinemann L.A., and Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75 (2007) 344-354
-
(2007)
Contraception
, vol.75
, pp. 344-354
-
-
Dinger, J.C.1
Heinemann, L.A.2
Kuhl-Habich, D.3
-
36
-
-
0030866776
-
Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group
-
Crook D. Multicenter study of endocrine function and plasma lipids and lipoproteins in women using oral contraceptives containing desogestrel progestin. UK Desogen Study Group. Contraception 55 (1997) 219-224
-
(1997)
Contraception
, vol.55
, pp. 219-224
-
-
Crook, D.1
-
37
-
-
1642329996
-
A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles
-
Gaspard U., Endrikat J., Desager J.P., Buicu C., Gerlinger C., and Heithecker R. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 69 (2004) 271-278
-
(2004)
Contraception
, vol.69
, pp. 271-278
-
-
Gaspard, U.1
Endrikat, J.2
Desager, J.P.3
Buicu, C.4
Gerlinger, C.5
Heithecker, R.6
-
38
-
-
0035068298
-
Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel
-
Knopp R.H., Broyles F.E., Cheung M., Moore K., Marcovina S., and Chandler W.L. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 63 (2001) 1-11
-
(2001)
Contraception
, vol.63
, pp. 1-11
-
-
Knopp, R.H.1
Broyles, F.E.2
Cheung, M.3
Moore, K.4
Marcovina, S.5
Chandler, W.L.6
-
39
-
-
0024561955
-
Oral contraceptives and lipids
-
Fotherby K. Oral contraceptives and lipids. BMJ 298 (1989) 1049-1050
-
(1989)
BMJ
, vol.298
, pp. 1049-1050
-
-
Fotherby, K.1
-
40
-
-
0028089149
-
Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone
-
Akerlund M., Almstrom E., Hogstedt S., and Nabrink M. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Acta Obstet Gynecol Scand 73 (1994) 136-143
-
(1994)
Acta Obstet Gynecol Scand
, vol.73
, pp. 136-143
-
-
Akerlund, M.1
Almstrom, E.2
Hogstedt, S.3
Nabrink, M.4
-
41
-
-
0031852621
-
Metabolic and endocrine effects of the desogestrel-containing oral contraceptive Mircette
-
Berga S.L. Metabolic and endocrine effects of the desogestrel-containing oral contraceptive Mircette. Am J Obstet Gynecol 179 (1998) S9-17
-
(1998)
Am J Obstet Gynecol
, vol.179
-
-
Berga, S.L.1
-
42
-
-
0034772212
-
Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation
-
Kemmeren J.M., Algra A., and Grobbee D.E. Effect of second and third generation oral contraceptives on lipid metabolism in the absence or presence of the factor V Leiden mutation. J Intern Med 250 (2001) 441-448
-
(2001)
J Intern Med
, vol.250
, pp. 441-448
-
-
Kemmeren, J.M.1
Algra, A.2
Grobbee, D.E.3
-
43
-
-
0036210707
-
An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables
-
Endrikat J., Klipping C., Cronin M., et al. An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variables. Contraception 65 (2002) 215-221
-
(2002)
Contraception
, vol.65
, pp. 215-221
-
-
Endrikat, J.1
Klipping, C.2
Cronin, M.3
-
44
-
-
0842324636
-
Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism
-
Scharnagl H., Petersen G., Nauck M., Teichmann A.T., Wieland H., and Marz W. Double-blind, randomized study comparing the effects of two monophasic oral contraceptives containing ethinylestradiol (20 microg or 30 microg) and levonorgestrel (100 microg or 150 microg) on lipoprotein metabolism. Contraception 69 (2004) 105-113
-
(2004)
Contraception
, vol.69
, pp. 105-113
-
-
Scharnagl, H.1
Petersen, G.2
Nauck, M.3
Teichmann, A.T.4
Wieland, H.5
Marz, W.6
-
45
-
-
0037501322
-
A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism
-
Gaspard U., Scheen A., Endrikat J., et al. A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism. Contraception 67 (2003) 423-429
-
(2003)
Contraception
, vol.67
, pp. 423-429
-
-
Gaspard, U.1
Scheen, A.2
Endrikat, J.3
-
46
-
-
0242286063
-
Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism
-
Ludicke F., Gaspard U.J., Demeyer F., Scheen A., and Lefebvre P. Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism. Contraception 66 (2002) 411-415
-
(2002)
Contraception
, vol.66
, pp. 411-415
-
-
Ludicke, F.1
Gaspard, U.J.2
Demeyer, F.3
Scheen, A.4
Lefebvre, P.5
-
47
-
-
0037228146
-
Progestogens with antiandrogenic properties
-
Raudrant D., and Rabe T. Progestogens with antiandrogenic properties. Drugs 63 (2003) 463-492
-
(2003)
Drugs
, vol.63
, pp. 463-492
-
-
Raudrant, D.1
Rabe, T.2
|